Your browser doesn't support javascript.
loading
Outcomes of patients with cobalamin C deficiency: A single center experience.
Bourque, Danielle K; Mellin-Sanchez, Lizbeth E; Bullivant, Garrett; Cruz, Vivian; Feigenbaum, Anette; Hewson, Stacy; Raiman, Julian; Schulze, Andreas; Siriwardena, Komudi; Mercimek-Andrews, Saadet.
Afiliação
  • Bourque DK; Division of Clinical and Metabolic Genetics, Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada.
  • Mellin-Sanchez LE; Division of Clinical and Metabolic Genetics, Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada.
  • Bullivant G; Division of Clinical and Metabolic Genetics, Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada.
  • Cruz V; Division of Clinical and Metabolic Genetics, Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada.
  • Feigenbaum A; Division of Clinical and Metabolic Genetics, Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada.
  • Hewson S; Division of Clinical and Metabolic Genetics, Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada.
  • Raiman J; Division of Clinical and Metabolic Genetics, Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada.
  • Schulze A; Division of Clinical and Metabolic Genetics, Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada.
  • Siriwardena K; Department of Pediatrics University of Toronto Toronto Ontario Canada.
  • Mercimek-Andrews S; Division of Clinical and Metabolic Genetics, Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada.
JIMD Rep ; 57(1): 102-114, 2021 Jan.
Article em En | MEDLINE | ID: mdl-33473346
ABSTRACT
Biallelic variants in MMACHC results in the combined methylmalonic aciduria and homocystinuria, called cobalamin (cbl) C (cblC) deficiency. We report 26 patients with cblC deficiency with their phenotypes, genotypes, biochemical parameters, and treatment outcomes, who were diagnosed and treated at our center. We divided all cblC patients into two groups group 1 SX group identified after manifestations of symptoms (n = 11) and group 2 NB group identified during the asymptomatic period via newborn screening (NBS) or positive family history of cblC deficiency (n = 15). All patients in the SX group had global developmental delay and/or cognitive dysfunction at the time of the diagnosis and at the last assessment. Seizure, stroke, retinopathy, anemia, cerebral atrophy, and thin corpus callosum in brain magnetic resonance imaging (MRI) were common in patients in the SX group. Global developmental delay and cognitive dysfunction was present in nine patients in the NB group at the last assessment. Retinopathy, anemia, and cerebral atrophy and thin corpus callosum in brain MRI were less frequent. We report favorable outcomes in patients identified in the neonatal period and treated pre-symptomatically. Identification of cblC deficiency by NBS is crucial to improve neurodevelopmental outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article